TSPO and Huntington disease: Interestingly, olesoxime, a neuroprotective cholesterol-like drug candidate which binds the voltage-dependent anion channels (VDACs) and the translocator protein (TSPO) on the outer mitochondrial membrane, was reported to ameliorate disease-related abnormalities in HD rodent models by lowering calpain activity (Clemens et al., 2015; Weber et al., 2016).